NAD+ (nicotinamide adenine dinucleotide) is an essential coenzyme involved in cellular energy production and DNA repair. NMN (nicotinamide mononucleotide) is an oral, direct precursor that the body converts into NAD+. Neither is a peptide, and neither is an approved drug, but both are commonly discussed alongside peptides in longevity research.
At a glance
| NAD+ | NMN (Nicotinamide Mononucleotide) | |
|---|---|---|
| What it is | Essential coenzyme (not a peptide) involved in cellular energy production and DNA repair, made by the body from dietary precursors | Nicotinamide mononucleotide, an oral direct precursor to NAD+; not a peptide |
| How it's thought to work | Cofactor for sirtuins (SIRT1 to SIRT7), proteins involved in DNA repair and energy metabolism; levels are described as declining with age | Converted to NAD+ through the salvage pathway, supplying the coenzyme used by sirtuins, PARP DNA-repair enzymes and mitochondrial energy metabolism |
| Regulatory status | Injectable NAD+ is not an FDA-approved treatment | Not an approved drug; in September 2025 the FDA concluded NMN is not excluded from the US dietary supplement definition |
| Strength of evidence | Aging research is mostly in animals and labs; a small 2019 human pilot study measured how infused NAD+ is processed | Small, short randomized trials report raised blood NAD+ and some metabolic effects; a 2026 meta-analysis found broad metabolic benefits not evident |
| Reported side effects | Flushing (warmth and discomfort) that typically passes within 15 to 30 minutes; nausea | Mild GI upset, headache, occasional flushing in short trials. Long-term data is limited |
| Supplied as | 100mg, 500mg, 1000mg | Capsules / powder |
| Mixing math example | 500 mg + 5 mL BAC water = 100,000 mcg/mL, 1 mg per unit | No reconstitution step |
Key differences
NAD+ itself acts as a cofactor for sirtuins, proteins involved in DNA repair, mitochondrial function and energy metabolism. NMN works one step earlier: it is converted into NAD+ through the salvage pathway, supplying the coenzyme for those same processes.
Injectable NAD+ is not an FDA-approved treatment. NMN is not an approved drug; in letters dated September 29, 2025, the FDA concluded that NMN is not excluded from the dietary supplement definition, reversing its earlier position. Availability and labeling vary by market.
NAD+ is associated with flushing that typically passes within 15 to 30 minutes, and nausea. Short human trials of NMN report mild GI upset, headache and occasional flushing.
What the research covers
Human research on directly administered NAD+ is small, including a 2019 pilot study of how infused NAD+ is processed. NMN has small, short randomized trials reporting higher blood NAD+ levels and some metabolic effects, and a 2026 meta-analysis of randomized trials found that broad metabolic benefits were not evident. Long-term human data is limited for both.
Sources
- A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour Intravenous Infusion of NAD+. Grant R et al. Frontiers in Aging Neuroscience, 2019. Human trial
- NAD+ in aging, metabolism, and neurodegeneration. Verdin E et al. Science, 2015. Review
- Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Yoshino M et al. Science, 2021. Human trial
- The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial. Yi L et al. Geroscience, 2023. Human trial
- Safety and Metabolism-Related Outcomes of Oral Nicotinamide Mononucleotide Supplementation in Adults: A Systematic Review and Meta-Analysis. Yang W et al. Nutrients, 2026. Review
- FDA Declares Nicotinamide Mononucleotide Is a Dietary Supplement. Venable LLP, 2025. Legal analysis
Frequently asked questions
What is the difference between NAD+ and NMN?
NAD+ is the coenzyme itself. NMN is a precursor that the body converts into NAD+ through the salvage pathway.
Are NAD+ and NMN peptides?
No. Neither is a peptide, though both are commonly discussed alongside peptides.
Is NAD+ or NMN FDA-approved?
Neither is an approved drug. Injectable NAD+ is not an FDA-approved treatment. In September 2025 the FDA concluded that NMN is not excluded from the US dietary supplement definition.
Does NMN raise NAD+ levels?
Small, short randomized trials report higher blood NAD+ levels after NMN, but a 2026 meta-analysis found broad metabolic benefits were not evident.
Both entries, plus the calculator
The PeptidesAI app covers NAD+, NMN (Nicotinamide Mononucleotide) and 68 other compounds, with a reconstitution calculator, a dose log and reminders. Free to download on iPhone.
Download on the App Store